Baxter International, Inc. Presents Additional Data from Phase 3 Study of Immunoglobulin for Alzheimer's Disease at AAIC

Published: Jul 16, 2013

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX) today presented additional data from the Phase III Gammaglobulin Alzheimer’s Partnership (GAP) study, including select analyses of subgroups, biomarker and imaging data, during the Alzheimer’s Association International Conference (AAIC) in Boston, Mass. The GAP study was conducted by Baxter and the Alzheimer’s Disease Cooperative Study (ADCS), a clinical trial consortium supported by the United States National Institute on Aging at the National Institutes of Health.

Help employers find you! Check out all the jobs and post your resume.

Back to news